Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Neovasc Inc. NVCN

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.


NDAQ:NVCN - Post by User

Comment by Barewoodon May 01, 2018 2:12pm
154 Views
Post# 27965689

RE:RE:RE:RE:RE:RE:Makstocks

RE:RE:RE:RE:RE:RE:MakstocksInterestingly, it seems Rimbus has gained a following thru persistently down grading Neovasc and stating the obvious; that is, what the Company has already made clear several times regarding dilution and risk. But there lies the difference: either you are invested in this Company and hence own it and effectively, not affectively, have researched the risks involved, or you are in it for quick profit as is Rimbus. I am not a pumper, but a share holder who is invested and sees significant possibilities in this even after its share consolidation. So, if this stock becomes even more diluted and the share price drops, I will add a significant lot more to my portfolio and ready this for the consolidation. Medical and Biotech are risky ventures regardless due to the nature of the competitiveness involved. Here is the link to Neovascs Filing of Annual Report on Form 20-F:

20-F

Read carefully and weigh the stated risks against the potential upside.

The Company has the following seven wholly-owned subsidiaries:

 

         
Name:
  Date of Incorporation:   Jurisdiction of Incorporation:

Neovasc Medical Inc. (formerly PM Devices Inc.)

  May 7, 1998   British Columbia

Neovasc Tiara Inc.

  March 11, 2013   Canada (federal)

Neovasc Medical Ltd.

  September 9, 2002   Israel

Neovasc (US) Inc. (formerly Medical Ventures (US) Inc.)

  July 2, 2007   United States

B-Balloon Ltd.(1)

  March 30, 2004   Israel

Neovasc GmbH

  August 14, 2017   Germany

Neovasc Management Inc.

  January 23, 2018   United States

(1)
B-Balloon Ltd. is in the process of being voluntarily wound up.

<< Previous
Bullboard Posts
Next >>